Encoded Therapeutics
PrivateLast Round
Series F
Sep 9, 2026
Total Funding Raised
$239.1M
Momentum
Top 1%
of companies Caplight tracks
Company Overview
Encoded Therapeutics is a biotechnology company developing precision genetic medicines for severe neurological disorders.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Precision Medicine, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Infrastructure
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Encoded Therapeutics Comparables
Compare Encoded Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Stoke Therapeutics, Inc. | 84% | |
| Neurogene | 79% | |
| Regel Therapeutics | 79% |
Encoded Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series F | Sep 9, 2026 | ||||
| Series D | Jul 22, 2020 | ||||
| Series C | Jun 26, 2019 | ||||
| Seed | Apr 18, 2017 | ||||
| Accelerator | Jul 30, 2015 | ||||
Accelerator | Oct 15, 2014 |
Key People
Founding team and executive leadership
Encoded Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Janus Henderson Group | Series F |
| SoftBank Investment Advisers | Series D, Series F |
| Farallon Capital Management | Series D, Series F |
| Boxer Capital | Series C, Series D |
| GV | Series D, Series F |
| Altitude Life Science Ventures | Series C, Seed |
| Braidwell | Series F |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 9, 2026
$275M round led by GV.
- Jun 7, 2026
ETX101 is the flagship clinical program for Dravet syndrome.
Recent news
Latest coverage and updates
- receives_financingSep 9, 2026
Encoded Therapeutics, Inc. received financing of $275M in Series F on Sep 9th '26.
- attends_eventSep 8, 2026
Encoded Therapeutics, Inc. attended event 16th European Epilepsy Congress on Sep 7th '26.
Encoded Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Encoded Therapeutics's valuation, stock price, and market status.
Is Encoded a public or private company?
Encoded is a private company.
What is the current stock price of Encoded?
Encoded is a private company with no public stock price. No recent secondary market data is available.
How much is Encoded worth (valuation)?
Valuation information for Encoded is not publicly available.
Can I buy Encoded stock?
Encoded shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Encoded's last funding round?
Encoded's most recent funding round was Series D on July 22, 2020.
Who are the main investors in Encoded?
Key investors in Encoded include GV, Menlo Ventures, Illumina Accelerator.
Will Encoded IPO soon?
No public IPO plans have been announced for Encoded.
How can I track Encoded secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Encoded's secondary market activity and sign up for updates.